HOME
ABOUT
Management
Board of Directors
ADDICTION
Alcohol Addiction
Limitations of Current AUD Therapies
Our Proposed Solution
TECHNOLOGY
Overview
Phase 2b Clinical Trial Results
History of Ondansetron Use for AUD
Strengths and Competitive Advantages
Newsroom
Press Releases
Media
INVESTORS
Overview
Analyst Coverage
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
CONTACT
HOME
ABOUT
Management
Board of Directors
ADDICTION
Alcohol Addiction
Limitations of Current AUD Therapies
Our Proposed Solution
TECHNOLOGY
Overview
Phase 2b Clinical Trial Results
History of Ondansetron Use for AUD
Strengths and Competitive Advantages
Newsroom
Press Releases
Media
INVESTORS
Overview
Analyst Coverage
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
CONTACT
ADIAL PHARMACEUTICALS’ CHIEF EXECUTIVE OFFICER FEATURED LIVE ON CHEDDAR’S ”CLOSING BELL”
16311
portfolio_page-template-default,single,single-portfolio_page,postid-16311,bridge-core-2.5.8,ajax_fade,page_not_loaded,,qode-theme-ver-24.3,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.2,vc_responsive
ADIAL PHARMACEUTICALS’ CHIEF EXECUTIVE OFFICER FEATURED LIVE ON CHEDDAR’S ”CLOSING BELL”
Category
Latests Media, News, News & Media
About This Project
Share